Meta analyses of RCTs and Food and Drug Administration (FDA) reports showed no difference in the risk of serious infection between TNF-α inhibitor monotherapy versus combination therapy with immunomodulators and/or systemic corticosteroid, although observational studies have reported an increased risk of infection with combination therapy [23–26]. This evidence concerns the gene TNF and infection.